Reducing antipsychotic dosage feasible, effective among patients with late-life schizophrenia

Results from an open-label, single-arm prospective study indicate that reducing dosage of antipsychotics is feasible among patients with late-life schizophrenia and can improve extrapyramidal symptoms, hyperprolactinemia and other symptoms related to increases in dopamine D2/3 receptor occupancies.

“Schizophrenia is a life-long illness that typically requires maintenance antipsychotic treatment throughout an individual’s life… Clinical guidelines developed by expert consensus recommend the use of lower doses of antipsychotics in older patients with schizophrenia. However, empirical data on age-specific antipsychotic dosing are limited,” study researcher Ariel Graff-Guerrero, MD, PhD, of the Centre for Addiction and Mental Health in Toronto, and colleagues wrote. Read more.

Tags: Brain PET Research

About NMC  |  Products  |  Quote  |  News  |  Resources  |  Contact  |  Sitemap